Challenges and Recent Advances of Novel Chemical Inhibitors in Medulloblastoma Therapy

Anand Maurya; Upendra Kumar Patel; Jitendra Kumar Yadav; Virender Pratap Singh; Alka Agarwal

doi:10.1007/978-1-0716-1952-0_13

Challenges and Recent Advances of Novel Chemical Inhibitors in Medulloblastoma Therapy

Methods Mol Biol. 2022:2423:123-140. doi: 10.1007/978-1-0716-1952-0_13.

Authors

Anand Maurya¹, Upendra Kumar Patel¹, Jitendra Kumar Yadav¹, Virender Pratap Singh¹, Alka Agarwal²

Affiliations

¹ Department of Medicinal Chemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
² Department of Medicinal Chemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India. agarwal.dralka@gmail.com.

PMID: 34978695
DOI: 10.1007/978-1-0716-1952-0_13

Abstract

Medulloblastoma is a common term used for the juvenile malignant brain tumor, and its treatment is exciting due to different genetic origins, improper transportation of drug across the blood-brain barrier, and chemo-resistance with various side effects. Currently, medulloblastoma divided into four significant subsections (Wnt, Shh, Group 3, and Group 4) is based on their hereditary modulation and histopathological advancement. In this chapter, we tried to combine several novel chemical therapeutic agents active toward medulloblastoma therapy. All these compounds have potent activity to inhibit the medulloblastoma.

Keywords: Brain tumor; IC50 value; Medulloblastoma; Shh group; Wnt group.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cerebellar Neoplasms* / drug therapy
Cerebellar Neoplasms* / genetics
Hedgehog Proteins / genetics
Humans
Medulloblastoma* / drug therapy
Medulloblastoma* / pathology

Substances

Hedgehog Proteins